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Background: To validate the expression of a urine-based bladder cancer associated diagnostic signature comprised
of 10 targets; ANG, CA9, MMP9, MMP10, SERPINA1, APOE, SDC1, VEGFA, SERPINE1 and IL8 in bladder tumor tissues.
Methods: Immunohistochemical analyses were performed on tumor specimens from 213 bladder cancer patients
(transitional cell carcinoma only) and 74 controls. Staining patterns were digitally captured and quantitated
(Aperio, Vista, CA), and expression was correlated with tumor stage, tumor grade and outcome measures.
Results: We revealed a positive association of 9 of the 10 proteins (excluding VEGF) in bladder cancer. Relative to
control cases, a reduction in SDC1 and overexpression of MMP9, MMP10, SERPINE1, IL8, APOE, SERPINA1, ANG
were associated with high stage bladder cancer. Reduced VEGF and increased SERPINA1 were associated with
high-grade bladder cancer. Disease-specific survival was significantly reduced in tumors with high expression of
SERPINE1 and/or IL8.
Conclusions: These findings confirm that the proteins in a urine-based diagnostic signature are aberrantly expressed
in bladder tumor tissues, and support the potential additional utility of selected biomarkers for the clinicopathological
evaluation of excised tissue or biopsy material.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_200
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Cancer of the urinary bladder is the fourth most common
malignancy in men and the ninth most common malig-
nancy in women in the United States [1]. Urothelial car-
cinomas constitute approximately 90% of all bladder
cancer (BCa) cases [2]. At presentation, more than 80% of
bladder tumors are non-muscle invasive bladder cancer
(NMIBC, i.e., Tis, Ta or T1) and the remaining 20% of
bladder tumors are muscle-invasive bladder cancers
(MIBC) or metastatic. NMIBC harbors a 5-year survival
rate of approximately 94% [3,4], however, approximately
70% of patients with these lesions develop tumor recur-
rence within two years of initial diagnosis. The recurrence* Correspondence: crosser@cc.hawaii.edu
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unless otherwise stated.phenomenon of NMIBC makes it one of the most preva-
lent cancers worldwide (in America it is second only to
colorectal cancer) and is, therefore, a great burden to
healthcare systems [1,5]. Though radiation with concomi-
tant chemotherapy is finding its place in the management
of MIBC, radical cystectomy is the mainstay of treatment
for these tumors, however, up to 50% of patients experi-
ence disease relapse and eventual death despite these ag-
gressive treatment regimens. Thus, the 5-year survival rate
for MIBC is approximately 50% [6,7]. These disappointing
outcomes may be explained by our limited understanding
of BCa tumorigenesis and progression.
The identification and validation of molecular alterations
involved in BCa tumorigenesis may lead to improved diag-
nostic tools and improved therapeutic planning and pa-
tient management. Previously, our group has developed a
novel urine-based BCa associated diagnostic signature
comprised of 10 targets; angiogenin (ANG), carbonicLtd. This is an Open Access article distributed under the terms of the Creative
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Table 1 Demographic, clinical and pathologic
characteristics of the 287 subjects comprising the study
cohort
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matrix metallopeptidase 10 (MMP10), Alpha-1 Antitryp-
sin (SERPINA1), Apolipoprotein E (APOE), Syndecan-1
(SDC1), Vascular endothelial growth factor A (VEGFA),
Plasminogen activator inhibitor-1 (SERPINE1) and Inter-
leukin 8 (IL8) [8-12]. The utility of the signature has been
confirmed in three large studies, one comprised of BCa
patients and controls with diverse benign conditions,
another comprised of BCa patients and controls collected
from multiple sites and analyzed in an independent
laboratory, and another comprised of patients on post-
treatment tumor surveillance for the monitoring of recur-
rence [13-15]. The multiplex BCa-associated diagnostic
signature has performed robustly in all of these scenarios.
In this study, we investigated the expression pattern of
the urine-based signature proteins in solid bladder tumor
tissue as a means to further substantiate our previously
validated urine-based signature for the detection of BCa.
Digital immunohistochemistry confirmed the aberrant ex-
pression of nine of the ten the biomarkers in bladder
tumor tissues and revealed that selected proteins in the
set had associations with stage and grade and clinical
outcome.
Methods
Patients and clinicopathologic information
The study was performed after approval by MD Anderson
Cancer Center Orlando Institutional Review Board under
a request of waiver of consent on archived pathologic
specimens within the Department of Pathology. The study
cohort was composed of 213 patients, who underwent
transurethral resection of bladder tumor, and 74 patients
without a history of BCa or extensive smoking history
(control), who underwent bladder biopsy for voiding dys-
function or autopsy at Orlando Health. Thus no patient
had neoadjuvant chemotherapy prior to tissue collection.
These paraffin embedded tissues were collected from
Jan 1, 2005 to December 31, 2010. From the medical re-
cords, the following information was retrieved: age, race,
sex, cancer related death. Data related to adjuvant chemo-
therapy was not available. Furthermore, histology (transi-
tional cell carcinoma only), tumor grade (2002 WHO
classification) and stage (2002 TNM classification) were
confirmed by reevaluation of the original pathology slides.
Demographic, clinical and pathologic characteristics of
the 287 subjects comprising the study cohort are illus-
trated in Table 1.
Immunohistochemistry
Immunostaining was performed using standard proto-
cols. Paraffin blocks were cut 5 μm sections and placed
on a Superfrost Plus Microslide. Sections were deparaffi-
nized followed by antigen retrieval using citric acid buf-
fer (pH 6.0, 95°C for 20 min). Slides were treated with1% hydrogen peroxide in methanol to block endogenous
peroxidase activity. After 20 min blocking in 5% horse
serum, slides were incubated overnight at 4°C with the fol-
lowing primary antibodies: anti-SERPINE1 (#HPA050039;
rabbit monoclonal, dilution 1:100) from Sigma Aldrich
(St. Louis, MO); anti-VEGFA (A-20) (#sc-152; rabbit poly-
clonal, dilution 1:500) and anti-ANG (#sc-74528; mouse
monoclonal, dilution 1:10) from Santa Cruz Biotechnol-
ogy, Inc. (Dallas, TX); anti-SDC1 [B-A38] (#ab34164,
mouse monoclonal, dilution 1:400), anti-MMP9 [EP1254]
(#ab76003, rabbit monoclonal, dilution 1:200), and anti-
MMP10 (#ab38930, rabbit polyclonal, dilution 1:2000)
from Abcam (Cambridge, MA); anti-CA9 (#23300002,
rabbit polyclonal, dilution 1:1000) and anti-SERPINA1
(#NBP1-90309, rabbit polyclonal, dilution 1:2500) from
Novus Biologicals (Littleton, CO); anti-APOE [3D12]
(#M068-3, mouse monoclonal, dilution 1:200) from MBL
Co. (Japan); and anti-IL8 (#AHC0881, rabbit polyclonal,
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NY). Next, slides were incubated with 2 μg/mL of bio-
tinylated anti-mouse or anti-rabbit IgG secondary anti-
body (Vector Laboratories, Burlingame, CA) for 30 min
at room temperature. Subsequently, the sections were
stained using Standard Ultra-Sensitive ABC Peroxidase
Staining kit (Pierce/Thermo Fisher Scientific, San Jose,
CA) and 3, 3′- diaminobenzidine (DAB; Vector Labora-
tories), counterstained by hematoxylin, dehydrated, and
mounted with a cover slide.
Based on the notable reports from Human Protein
Atlas (http://www.proteinatlas.org), lung (SERPINE1 and
MMP9), liver (VEGF, ANG, CA9 and SERPINA1), tonsil
(SDC1, MMP10 and APOE) and stomach (IL8) were used
as a positive control and omitting the primary antibody
served as the negative control.Image analysis
Immunostained slides (n = 287) were scanned into high-
resolution images using the Aperio Scanscope Cs (Aperio
Technologies, Vista, CA) with a 20x objective as previ-
ously described [16,17]. The images were then visualized
in the software Image Scope (Aperio, Vista, CA, USA).
Briefly, the location of immunoreactivity was noted. All
immunostaining was cytoplasmic except SDC1, which was
present in the cellular membrane or cytoplasma, based on
grade or stage. All epithelial staining analyzed for this
study. The selection of the regions of interest (ROI) on
the training slides was initially done by an experienced
pathologist (AL) and a technician (GZ) working together.
After a training period, the technician, who was blinded to
disease status, did the selection of the areas in cases where
tumor cell areas were easily identifiable in the section.
Using an algorithm developed in Aperio Scanscope Cs,
staining intensity of the tissue, as well as the extent (per-
centage) of staining in cells was measured for each target.
Then for statistical purposes, the ranked set of data for
each target was divided into four groups with 1st quartile
having the lowest staining intensity (0 - 10%) and the 4th
quartile having the highest staining intensity (>50%). The
quantitative immunochemistry slides were then reviewed
and corroborated independently by a pathologist (AL).
Whenever a discrepancy between the quantitative and
semi-quantitative readings occurred, another investigator
(CJR) reviewed and rendered a final score.Statistical analysis
SAS V9.4 (Cary, NC) was used to perform statistical
analyses. The relationship between immunoexpression
of the 10 targets and clinicopathological features were
tested with a cross tables applying Chi-square or Fisher
test, and all tests were 2-tailed. The Kaplan-Meier curves
using the log-rank test were used to estimate andcompare disease-specific survival. A p value of <0.05 was
considered significant.
Results and discussion
Demographics of the patients and tumor characteristics
The age of the cancer patients ranged from 30 to
94 years (mean ± SD, 71.8 ± 11.9). Seventy-six percent of
the cancer patients were male and 76% of the cancer pa-
tients were Caucasian. Seventy patients (33%) had a his-
tory of BCa. Twelve percent of patients had tumors
larger than 5 cm, 64% had tumors between 2 and 5 cm,
while 23% had tumors <2 cm (Table 1). All tumors were
confirmed to be transitional cell carcinoma. The tumors
were classified as either low-grade (26 [12.2%]) or high-
grade (175 [82.2%]) and Tis, Ta, T1 (non-muscle invasive
bladder cancer 131 [61.5%]) and T2-T4, N+, M+(muscle
invasive bladder cancer 70 [32.9%]). In 12 cases, lim-
ited tissues were available for accurate stage and grade
assessment.
Immunohistochemical results
Figure 1 shows representative expression status for each
of the 10 targets in a high-grade non-muscle invasive
tumor. The relationship between immunophenotype for
each target and disease status is summarized in Table 2.
Expression of 9 of the 10 biomarkers (not VEGF) showed
a positive association with cancer. In our study, we found
cancer cases expression levels in the 3rd and 4th quartile
for MMP9 (66.5% vs. 9.5% of control), MMP10 (60.1% vs.
25.7% of control), SERPINE1 (57.3% vs. 31.9% of control),
IL8 (49.5% vs. 41.5% of control), CA9 (57.2% vs. 30.0% of
control), APOE (61.7% vs. 18.3% of control), SERPINA1
(59.6% vs. 25.5% of control), SDC1 (66.5% vs. 7.1% of con-
trol) and ANG (67.9% vs. 0% of control) to be significantly
increased compared to control.
The relationship between immunophenotype for each
target and tumor grade is summarized in Table 3. We
found only high-grade disease expression level in the
3rd and 4th quartile for SERPINA1 (62.4% vs. 45.4% of
low-grade) to be significantly increased compared to
low-grade disease. Interestingly, we found that VEGFA
expression levels in the high-grade disease 3rd and 4th
quartile were significantly reduced compared to low-
grade disease (40.3% vs. 70.9, respectively, p =0.031).
The relationship between immunophenotype for each
target and tumor stage is summarized in Table 4. High
stage disease correlated with increased expression level
(i.e., more 3rd and 4th quartile immunostaining) for
MMP9, MMP10, SERPINE1, IL8, APOE, SERPINA1 and
ANG. As we have previously reported [18], a shift in cellu-
lar location of SDC1 (membrane to cytoplasm) was noted
in high stage disease. This change in the location of SDC1
protein, resulted in an inverse association with SDC1 cell
membrane expression level.
Figure 1 Representative expression status for ANG, CA9, MMP9, MMP10, SERPINA1, APOE, SDC1, VEGFA, serpine1 and IL8 levels in
tumor tissue. Insert Representative expression status for ANG, CA9, MMP9, MMP10, SERPINA1, APOE, SDC1, VEGFA, serpine1 and IL-8 levels in
benign tissue. All images were captured at 400× magnification.
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The follow-up period for the cohort ranged from 1 to
82 months (median 6 months), and the mean survival
time was 16 months. Using Kaplan-Meier survival ana-
lysis with the log-rank test, we found significantly worse
disease-specific survival (DSS) when the expression levels
of SERPINA1 or IL8 were increased. On multivariate ana-
lysis when controlling for stage and grade, biomarker
levels did not independently predict DSS (data not
shown). For statistical purposes when analyzing KM
curves for the combination of SERPINA1 and IL8,
quartile 1 and 2 were combined and compared to the
combination of quartile 3 and 4. Based on these results,
we re-analyzed SERPINA1 and IL8 immunostaining in
the following combinations: SERPINA1 1st/2nd quartile
with IL8 1st/2nd quartile; SERPINA1 3rd/4th quartile
with IL8 1st/2nd; SERPINA1 1st/2nd quartile with IL8
3rd/4th quartile; SERPINA1 3rd/4th quartile with IL8
3rd/4th quartile. When both SERPINA1 and IL8 expres-
sion were increased, survival was significantly reduced
compared to assessment of SERPINA1 alone or IL8
alone (p =0.0048) (Figure 2).
Previously, we have employed proteomic [19,20] and
genomic analyses [21,22] of urine components to identify
accurate and robust molecular signatures for the non-
invasive diagnosis of BCa. A candidate 14-biomarker urinary
protein signature was subsequently tested in an inde-
pendent cohort composed of 127 patients (64 BCa) [8-12].
That study narrowed the diagnostic signature to 10
biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA,ANG, CA9, APOE, SDC1 and SERPINE1), and this
was validated in a cohort of 308 patients (102 BCa) with
varying benign urologic diagnoses [13]. Furthermore,
using an independent test laboratory, we externally vali-
dated these results in a multi-institute cohort comprised
of 320 patients (183 BCa). The 10-biomarker signature
achieved 79%, specificity of 79% (AUROC 0.846) for non-
invasive BCa detection in phase II external validation
study [14]. Based on these results, the multiplex urine-
based signature is the focus of development into a clinical
test.
In our previous work, the non-invasively obtained ma-
terial (urine) was directly subjected to molecular profiling
for biomarker discovery. This strategy was chosen to avoid
the potential drop-out of biomarkers that can occur when
translating from tissue-based discovery studies [23-25]
to biological fluids for assay development. A number of
tissue-based biomarkers have translated to urinalysis
[26-28], but translation can be affected by secretion
rate, enzymatic breakdown or the stability of the protein
in the dilute media. Furthermore, urine as a discovery ma-
terial also has the advantages of being relatively easy to
obtain, including the chance for serial sampling, and be-
cause of its relatively low complexity compared to solid
tissue or blood.
Here, we investigated the expression patterns of our
urine-based biomarker panel in excised bladder tumor tis-
sue. Of the 10 biomarkers tested, all but VEGFA had over-
expression of the biomarkers compared to control tissues.
Additionally, elevated levels of SERPINA1 and reduced
Table 2 Relationship between immunochemical features and disease status
Target expression Bladder cancer, % Benign, % p-value Target expression Bladder cancer, % Benign, % p-value
VEGFA APOE
1 47 (28.7%) 12 (16.2%) 0.115 1 30 (15.5%) 36 (50.7%) <0.0001
2 2 44 (22.8%) 22 (31.0%)
3 3 54 (28.0%) 12 (16.9%)
4 4 65 (33.7%) 1 (1.4%)
MMP9 SERPINA1
1 14 (7.7%) 50 (67.6%) <0.0001 1 35 (18.8%) 30 (40.5%) <0.0001
2 47 (25.8%) 17 (23.0%) 2 40 (21.5%) 25 (33.8%)
3 60 (33.0%) 4 (5.4%) 3 49 (26.3%) 16 (21.6%)
4 61 (33.5%) 3 (4.1%) 4 62 (33.3%) 3 (4.1%)
MMP10 SDC1
1 37 (20.2%) 27 (36.5%) <0.0001 1 27 (14.6%) 36 (51.4%) <0.0001
2 36 (19.7%) 28 (37.8%) 2 35 (18.9%) 29 (41.4%)
3 46 (25.1%) 18 (24.3%) 3 60 (32.4%) 4 (5.7%)
4 64 (35.0%) 1 (1.4%) 4 63 (34.1%) 1 (1.4%)
SERPINE1 ANG
1 47 (25.7%) 16 (22.2%) <0.0001 1 4 (2.1%) 62 (86.1%) <0.0001
2 31 (16.9%) 33 (45.8%) 2 56 (29.0%) 10 (13.9%)
3 46 (25.1%) 18 (25.0%) 3 66 (34.2%) 0 (0%)
4 59 (32.2%) 5 (6.9%) 4 67 (34.7%) 0 (0%)
IL8
1 56 (28.6%) 10 (24.3%) <0.0001
2 43 (21.9%) 24 (34.3%)
3 36 (18.4%) 30 (32.9%)
4 61 (31.1%) 6 (8.6%)
CA9
1 35 (17.9%) 31 (44.3%) <0.0001
2 49 (25.0%) 18 (25.7%)
3 48 (24.5%) 18 (25.7%)
4 64 (32.7%) 3 (4.3%)
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and elevated levels of MMP9, MMP10, SERINE1, IL8,
APOE, SERPINA1 and ANG (and reduced levels of SDC1)
were associated with high stage BCa. High expression
levels of SERPINA1 and IL8 were associated with a reduc-
tion in disease-specific survival, and when both SERPINA1
and IL8 were highly expressed there was a significant re-
duction in survival (p = 0.0048). Furthermore, many of
these biomarkers are cytokines (e.g. IL8 and VEGF) thus
‘bleeding’ of biomarkers into stroma would be expected
and was noted. These findings validate the inclusion of the
majority of the urine-based biomarkers in a non-invasive
BCa diagnostic signature but also suggest that some of the
same biomarkers may have utility in prognostic evaluation
when monitored in solid tissue and perhaps in urine.A number of molecular changes have been associated
with development and progression of BCa. Such molecu-
lar changes include 1) alterations in expression and regu-
lation of the receptor tyrosine kinases, fibroblast growth
factor receptor 3, and members of the epidermal growth
factor receptor family, 2) upregulation of signaling
through RAS and phosphatidylinositol 3-kinase/AKT
pathways, and 3) functional down-regulation of the tumor
suppressors, p53, pRb, and p16 through deletion, mutation
and/or silencing [29-31]. Thus further understanding the
molecular mechanisms underpinning the development of
aggressive tumor growth in BCa is pivotal to 1) understand
tumor biology, 2) effectively diagnosing BCa, 3) exploiting
the prognostic capabilities and 4) identifying novel targets
for pharmacological intervention.
Table 3 Relationship between immunochemical features and tumor grade
Target expression Low-grade, % High-grade, % p-value Target expression Low-grade, % High-grade, % p-value
VEGFA APOE
1 4 (16.7%) 43 (30.9%) 0.031 1 6 (25.0%) 24 (14.7%) 0.598
2 3 (12.5%) 40 (28.8%) 2 5 (20.8%) 39 (23.9%)
3 7 (29.2%) 30 (21.6%) 3 5 (20.8%) 46 (28.2%)
4 10 (41.7%) 26 (18.7%) 4 8 (33.3%) 54 (33.1%)
MMP9 SERPINA1
1 3 (12.5%) 10 (6.5%) 0.161 1 2 (9.1%) 32 (20.4%) 0.021
2 9 (37.5%) 36 (23.5%) 2 10 (45.5%) 27 (17.2%)
3 8 (33.3%) 50 (32.7%) 3 5 (22.7%) 43 (27.4%)
4 4 (16.7%) 57 (37.3%) 4 5 (22.7%) 55 (35.0%)
MMP10 SDC1
1 7 (29.2%) 29 (19.0%) 0.611 1 2 (8.0%) 25 (15.7%) 0.222
2 3 (12.5%) 32 (20.9%) 2 3 (12.0%) 31 (19.5%)
3 6 (25.0%) 39 (25.5%) 3 7 (28.0%) 53 (33.3%)
4 8 (33.3%) 53 (34.6%) 4 13 (52.0%) 50 (31.4%)
SERPINE1 ANG
1 10 (41.7%) 34 (22.4%) 0.213 1 0 (0%) 4 (2.5%) 0.783
2 4 (16.7%) 27 (17.8%) 2 7 (29.2%) 47 (28.8%)
3 5 (20.8%) 38 (25.0%) 3 7 (29.2%) 56 (34.4%)
4 5 (20.8%) 53 (34.9%) 4 10 (41.7%) 56 (34.4%)
IL8
1 9 (37.5%) 43 (26.2%) 0.699
2 4 (16.7%) 37 (22.6%)
3 4 (16.7%) 32 (19.5%)
4 7 (29.2%) 52 (31.7%)
CA9
1 7 (30.4%) 28 (16.9%) 0.206
2 6 (26.1%) 40 (24.1%)
3 2 (8.7%) 43 (25.9%)
4 8 (34.8%) 55 (33.1%)
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have a varied range of ascribed functions including angio-
genesis, breakdown of extracellular matrix, serine protein
inhibitor, catalyze the reversible hydration of carbon di-
oxide, lipoprotein metabolism and cell binding/signal-
ing (Table 5) with the two principal ascribed functions,
angiogenesis (IL8, VEGFA and ANG) and breakdown of
extracellular matrix (MMP9 and MMP10). In fact,
MMP9, MMP10 and SERPINE1 [32-34] have also been
associated with angiogenesis. Angiogenesis, the devel-
opment of new blood vessels from existing blood ves-
sels, is essential for normal growth and development of
tissues and organs. A balance of pro-angiogenic factors
and anti-angiogenic factors tightly controls this process
[35-37]. However in solid tumors, the balance mayfavor pro-angiogenic factors and thus the ability to sus-
tain this abnormal growth of tissue [38]. Furthermore
in addition to MMP9 and MMP10 degrading extracel-
lular matrix, recent studies have suggested that ANG
and SERPINE1 can breakdown the extracellular matrix
[39,40]. Degradation of the extracellular matrix allows
cells to become more motile. Thus, working in con-
junction with the increase in vasculature to increase
the probability that motile-invasive tumor cells may
enter the circulation to disseminate to distant organs
[41]. The extent of tumor vascularization differs be-
tween malignancies, and has been shown to correlate
directly with metastatic potential [42].
Our study has important limitations. First, although
this is a rather large study with specimens from 213 BCa
Table 4 Relationship between immunochemical features and tumor stage
Target expression Ta Tis (CIS) T1 T2 >T3, N+ or M+ p-value Target expression Ta Tis (CIS) T1 T2 >T3, N+ or M+ p-value
VEGFA APOE
1 10 (25.0%) 5 (29.4%) 18 (33.3%) 6 (25.0%) 8 (28.6%) 0.670 1 13 (27.7%) 1 (6.3%) 9 (15.3%) 7 (24.1%) 0 (0%) 0.009
2 6 (15.0%) 5 (29.4%) 17 (31.5%) 6 (25.0%) 9 (32.1%) 2 14 (29.8%) 6 (37.5%) 14 (23.7%) 5 (17.2%) 5 (13.9%)
3 10 (25.0%) 4 (23.5%) 9 (16.7%) 7 (29.2%) 7 (25.0%) 3 10 (21.3%) 5 (31.3%) 13 (22.0%) 6 (20.7%) 17 (47.2%)
4 14 (35.0%) 3 (17.6%) 10 (18.5%) 5 (20.8%) 4 (14.3%) 4 10 (21.3%) 4 (25.0%) 23 (39.0%) 11 (37.9%) 14 (38.9%)
MMP9 SERPINA1
1 5 (11.6%) 4 (7.1%) 4 (13.8%) 0.036 1 11 (25.0%) 2 (13.3%) 16 (27.6%) 3 (10.7%) 2 (5.9%) 0.036
2 15 (34.9%) 5 (35.7%) 16 (28.6%) 4 (13.8%) 5 (14.3%) 2 10 (22.7%) 2 (13.3%) 12 (20.7%) 9 (32.1%) 4 (11.8%)
3 13 (30.2%) 5 (35.7%) 22 (39.3%) 7 (24.1%) 11 (31.4%) 3 10 (22.7%) 4 (26.7%) 19 (32.8%) 6 (21.4%) 9 (26.5%)
4 10 (23.3%) 4 (28.6%) 14 (25.0%) 14 (48.3%) 19 (54.3%) 4 13 (29.5%) 7 (46.7%) 11 (19.0%) 10 (35.7%) 19 (55.9%)
MMP10 SDC1
1 11 (25.6%) 8 (57.1%) 12 (21.8%) 2 (6.9%) 3 (8.3%) 0.036 1 6 (14.3%) 4 (21.1%) 5 (8.5%) 5 (17.2%) 7 (20.0%) 0.021
2 9 (20.9%) 2 (14.3%) 10 (18.2%) 8 (27.6%) 6 (16.7%) 2 9 (21.4%) 6 (31.6%) 5 (8.5%) 8 (27.6%) 6 (17.1%)
3 10 (23.3%) 3 (21.4%) 12 (21.8%) 9 (31.0%) 11 (30.6%) 3 13 (31.0%) 6 (31.6%) 17 (28.8%) 8 (27.6%) 16 (45.7%)
4 13 (30.2%) 1 (7.1%) 21 (38.2%) 10 (34.5%) 16 (44.4%) 4 14 (33.3%) 3 (15.8%) 32 (54.2%) 8 (27.6%) 6 (17.1%)
SERPINE1 ANG
1 19 (45.2%) 8 (53.3%) 12 (21.4%) 2 (7.1%) 3 (8.6%) 0.0003 1 0 (0%) 1 (5.9%) 0 (0%) 3 (10.3%) 0 (0%) <0.0001
2 7 (16.7%) 1 (6.7%) 11 (19.6%) 4 (14.3%) 8 (22.9%) 2 23 (50.0%) 8 (47.1%) 16 (27.1%) 6 (20.7%) 1 (2.8%)
3 9 (21.4%) 5 (33.3%) 15 (26.8%) 5 (17.9%) 9 (25.7%) 3 12 (26.1%) 2 (11.8%) 24 (40.7%) 10 (34.5%) 15 (41.7%)
4 7 (16.7%) 1 (6.7%) 18 (32.1%) 17 (60.7%) 15 (42.9%) 4 11 (23.9%) 6 (35.3%) 19 (32.2%) 10 (34.5%) 20 (55.6%)
IL8
1 19 (41.3%) 7 (43.8%) 20 (33.3%) 4 (13.8%) 2 (5.4%) 0.001
2 12 (26.1%) 3 (18.8%) 16 (26.7%) 4 (13.8%) 6 (16.2%)
3 6 (13.0%) 1 (6.3%) 11 (18.3%) 10 (34.5%) 8 (21.6%)
4 9 (19.6%) 5 (31.3%) 13 (21.7%) 11 (37.9%) 21 (56.8%)
CA9
1 12 (26.7%) 4 (23.5%) 10 (16.7%) 7 (24.1%) 2 (5.3%) 0.308
2 12 (26.7%) 5 (29.4%) 9 (15.0%) 6 (20.7%) 14 (36.8%)
3 9 (20.0%) 3 (17.6%) 17 (28.3%) 6 (20.7%) 10 (26.3%)















Figure 2 Univariate analysis of the prognostic impact of SERPINA1 and IL8 co-over-expression on disease-specific survival of bladder
cancer patients.
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would ideally like to have an even larger cohort. Second,
the majority of our tumors assessed were high-grade tu-
mors, which reflects the tertiary nature of our facility.
Next due to the limited dataset, we could not evaluate
these biomarkers for distinguishing progressive NMIBC
from non-progressive NMIBC as well as progressive
MIBC from non-progressive MIBC. With this study
serving as proof of principle, we are now in the processTable 5 Annotated urine-based bladder cancer associated dia
Full name Abbreviation Ascribed function





Matrix metallopeptidase 9 MMP9 breakdown of extracellular m
Matrix metallopeptidase 10 MMP10 breakdown of extracellular m
Serpin peptidase inhibitor SERPINA1 serine protease inhibitor
Serpin peptidase inhibitor SERPINE1 serine endopeptidase inhibit
Carbonic anhydrase IX CA9 catalyze the reversible hydra
of carbon dioxide
Apolipoprotein E APOE Lipoprotein catabolism and m
Syndecan 1 SDC1 cell binding, cell signaling, cy
organizationof designing a larger, prospective study that can assess
these factors. Control cohort is not age matched to BCa
cohort. This is not surprising since the average age for
bladder cancer patient undergoing transurethral bladder
resection was 71 years while the average age for controls
undergoing bladder biopsy for voiding dysfunction was
39 years. We believe this age discrepancy is of limited
clinical significance. Ideally, we would have had corre-
sponding urine to analyze the biomarker signature viagnostic
Location Interacts with other
members of signature
esis Extracellular MMP9, SDC1
Extracellular, nucleus None
Extracellular, cytoplasm None
atrix Extracellular IL8, MMP10
atrix Extracellular MMP9
Extracellular None
or Extracellular, plasma membrane None
tion Plasma membrane None
etabolism Extracellular, plasma membrane,
cytoplasm
None
toskeletal Plasma membrane, cytoplasm IL8
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http://www.diagnosticpathology.org/content/9/1/200ELISA to document elevated urinary as well as tissue
biomarkers in this cohort. However we do not think this
distracts since we have previously validated the urinary
levels of the signature in over 800 clinical samples
[12-15] studies to directly compare urinary protein levels
with immunoreactivity levels.
Clinically, accurate BCa assays may have a clear impact
on initial diagnostic performance, and on the long-term
clinical management of BCa patients. If reliable urinary
diagnostic biomarker assays can reduce the number of in-
vasive and uncomfortable cystoscopies, then improve-
ments in patient compliance and satisfaction will likely
follow. Furthermore, the increased diagnostic efficiency
and cost-savings from such assays will benefit both the pa-
tients and the healthcare systems. The ultimate goal is to
be able to detect BCa in a timely manner such that the pa-
tient can expect an improved survival as well as improved
quality of life.
Conclusions
BCa disease management is hampered by lack of diagnos-
tic or prognostic markers capable of a) predicting disease
and b) predicting the likely disease course. Thus, there is
an urgent need for identification and characterization of
the molecular alterations that underlie lethal disease and
that identifies more aggressive tumors early for radical
and/or novel therapies. The present work shows that
the expression patterns of the biomarkers in our BCa-
associated diagnostic signature are largely reflected in
solid tumor tissues and specific associations with grade
and stage and DSS were revealed. A combination of
these immunohistochemical biomarkers may aid in tissue
evaluation with respect to diagnosis of malignancy or in
predicting the behavior of individual BCa cases, and if
confirmed, some of the targets may represent potential
therapeutic targets for human urothelial cancer.
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